x
ServiziMenu principaleHome
Facebook Twitter Linkedin Print
Home > News

News

IRST-AUSL Romagna breast cancer Conference: From molecular signature to clinical oncology

19.06.2025

CCCRN - Comprehensive Cancer Care and Research Network

Rimini, 19-20 giugno 2025

Centro Congressi SGR

Scarica il Programma in PDF

Ruoli e responsabilità degli attori della ricerca clinica: gestione, conduzione e monitoraggio di uno studio clinico

07.05.2025

7 maggio - 28 maggio 2025 - 11 giugno 2025

FAD WEBINAR

Responsabile scientifico: Antonino Musolino

Scarica il Programma in PDF

Empowering talks: state of the art and translational research in Breast and Ovarian Cancer

04.04.2025

4 aprile 2025

Star Hotel du Parc
Parma

Scarica il Programma in PDF

L’evoluzione della medicina di precisione e personalizzata in oncologia: il ruolo della ricerca clinica accademica

28.03.2025

28-29 marzo 2025
HOTEL NH BOLOGNA DE LA GARE
Bologna

Scarica il Programma in PDF

Impact of edoxaban-related adverse events in patients with cancer experiencing venous thromboembolism during antineoplastic therapy: Results of the phase IV EDOI study (GOIRC-05–2018)

09.02.2025

Scarica il documento in PDF

An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line

13.01.2025

Scarica il documento in PDF

Bridging bench to bedside: The evolution and impact of translational research in oncology. The experience of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)

13.01.2025

Scarica il documento in PDF

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years’ Follow-Up

09.01.2025

Scarica il documento in PDF

Adjuvant Pertuzumab and Trastuzumab in EarlyHuman Epidermal Growth Factor Receptor 2-PositiveBreast Cancer in the APHINITY Trial: Third InterimOverall Survival Analysis With Efficacy Update

08.01.2025

Scarica il documento in PDF

Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study

07.01.2025

Scarica il documento in PDF

Righe per pagina: 
Apri